Kananji Pharmaceutical Technology

Kananji Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative small molecule therapeutics for endocrine-related diseases and oncology. The company focuses on modulating nuclear receptors, particularly targeting the androgen and estrogen pathways to treat conditions such as prostate cancer and endometriosis. Their lead programs include novel androgen receptor antagonists and selective progesterone receptor modulators designed to offer improved efficacy and safety profiles over existing treatments. Kananji leverages its internal R&D capabilities to advance a pipeline of candidates through early and mid-stage clinical trials. The company aims to address significant unmet medical needs in the Chinese and global markets through precision medicine approaches.